Alzchem Group Ag Stock Earnings Reports

AlzChem delivered a strong first half of 2026: group revenue rose 6% y/y to ~EUR 304m and EBITDA increased 14% to EUR 64.5m, lifting the EBITDA margin to 21.2%. Specialty Chemicals (70% of group sales) was the main growth and margin driver—revenue +10% to EUR 214m—supported by creatine (Creapure/Creavitalis), nitroguanidine (NQ) demand, and custom manufacturing. Basics & Intermediates was broadly stable (H1 revenue EUR 75.4m), impacted by weak agricultural demand and a scheduled carbide furnace refurbishment (recommissioning targeted for September). Operational progress: German nitroguanidine expansion and a new guanidine plant entered commissioning; site decision made for a US NQ plant in Bushy Park, SC (construction targeted from 2027, ramping toward 2029). Financing: the group secured up to EUR 100m in growth financing (EUR 80m drawn plus committed facilities), refinanced near-term debt and strengthened liquidity. Balance sheet and cash flow remain healthy (operating cash flow EUR 51m), with H1 net income and EPS up ~14%. Guidance confirmed for FY26: sales ~EUR 600m and EBITDA ~EUR 126m (organic growth driven by Specialty Chemicals). Key near-term considerations for investors: (1) Q3 may be softer after some sales were pulled into H1, (2) ramp-up costs (low single-digit millions) for new/overhauled plants may weigh on H2 sequential EBITDA, (3) agriculture end-market remains weak (lower farmer profitability and competition from imports), and (4) management expects to be able to pass through raw material/energy cost increases but monitors geopolitical and energy-market risks.